The Maharashtra government filed a petition with the Supreme Court on Tuesday, June 1, contesting the Bombay High Court’s ruling mandating the state to establish a centralized system for the acquisition and distribution of the antiviral medicine Remdesivir.
The court linked the request with the suo moto covid case In Re Distribution of Essential Supplies and Services during Pandemic, which was examined by Justice DY Chandrachud, Justice L. Nageswara Rao, and Justice S. Ravindra Bhat.
On May 3, the Bombay High Court’s Nagpur Bench ordered the Maharashtra government’s Chief Health Secretary and State Commissioner of the Food and Drug Administration to “take efforts to centralize the system for the acquisition, allocation, and distribution of Remdesivir.” The judgment was made at a hearing on its suo motu PIL on covid-19 administration in Maharashtra’s Nagpur and Vidarbha areas.
As a result, the Court said that it will issue directives to the Secretary of State and the FDA, and that these directives would be strictly obeyed. To maintain a consistent supply of Remdesivir to Nagpur and other areas of Vidhabha, the court ordered the FDA to upload the weekly distribution of Remdesivir vials throughout the State and provide a daily report on the vials delivered and the backlog.